Skip to main content
Abattis Bioceuticals Corp. logo

Abattis Bioceuticals Corp. — Investor Relations & Filings

Ticker · ATTBF ISIN · CA00258G1037 LEI · 5493000GEXZZJ997G829 CSE Professional, scientific and technical activities
Open in API
Filings indexed 442 across all filing types
Latest filing 2021-03-20 Legal Proceedings Report
Country CA Canada
Listing CSE ATTBF

About Abattis Bioceuticals Corp.

https://www.abattis.com

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company. Its core business involves aggregating, integrating, and investing in cannabis technologies and related biotechnology services. The company is engaged in the development and licensing of natural health products and health solutions, often focusing on applications for chronic illnesses in human and animal health sectors, particularly within the framework of the legal cannabis industry.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Legal Proceedings Report Classification · 95% confidence The document is a detailed announcement from Abattis Bioceuticals Corp. regarding the resolution of legal and regulatory issues, including the British Columbia Securities Commission's review and a class action lawsuit. It discusses the history of regulatory allegations, cease trade orders, legal proceedings, management and board changes, and the company's efforts to file financial statements and resume trading. The document also includes a resignation announcement of the CEO and messages from the CEO and Board. There are no actual financial statements or detailed financial data presented, nor is this a transcript, proxy, or earnings release. The content focuses on legal proceedings and management changes related to regulatory compliance and litigation outcomes. Given the emphasis on legal and regulatory updates and the absence of financial report data, the document best fits the category of Legal Proceedings Report (LTR).
2021-03-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the delay of the company's interim financial statements for the nine months ended June 30, 2020, due to regulatory extensions granted by Canadian securities regulators. It references the expected filing date of the interim filings (financial statements, MD&A, and certifications) but does not contain the actual financial statements or substantive financial data. The document is primarily an announcement about the delay and expected filing date, not the interim report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about filing delays and extensions rather than the interim report (IR) itself.
2020-09-01 English
News release - English.pdf
Regulatory Filings
2020-07-28 English
52-109F2R - Certification of refiled interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification filed by the CFO of Abattis Bioceuticals Corp regarding the refiled interim Management's Discussion and Analysis (MD&A) for the interim period ended June 30, 2019. It is a certification form (Form 52-109F2R) confirming the accuracy and fair presentation of the interim filings. The document does not contain actual financial statements or substantive financial data but is an officer certification related to interim filings. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself. The document length is short (3145 characters), and it is primarily a certification letter, not the interim report or MD&A itself.
2020-07-28 English
52-109F2R - Certification of refiled interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification filed by the CEO of Abattis Bioceuticals Corp regarding the refiled interim Management's Discussion and Analysis (MD&A) for the interim period ended June 30, 2019. It is a certificate confirming the review and fair presentation of the interim filings, specifically an interim MD&A. The document is short (3130 characters) and primarily serves as an officer certification rather than containing substantive financial data or the interim report itself. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR).
2020-07-28 English
Interim MD&A (amended) - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management Discussion and Analysis For the nine months ended June 30, 2019 Amended' and contains detailed discussion of financial results, business activities, acquisitions, share issuances, management changes, and financial highlights for the nine-month period ending June 30, 2019. It references compliance with National Instrument 51-102F1, which governs MD&A disclosures. The document includes substantive financial data, analysis of quarterly results, and management's explanation of business trends and outlook. It is not a brief announcement or a certification letter, nor is it a transcript, presentation, or proxy statement. Therefore, this document fits the category of Management Reports (MDA).
2020-07-28 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.